Vanda Pharmaceuticals Settles Hetlioz LQ Patent Litigation With MSN

PUBT · 1d ago
Vanda Pharmaceuticals Settles Hetlioz LQ Patent Litigation With MSN
  • Vanda Pharmaceuticals settled HETLIOZ LQ patent litigation with MSN Pharmaceuticals and MSN Laboratories on Nov. 16, 2026.
  • MSN received a nonexclusive, royalty-free license to market generic tasimelteon oral suspension in the U.S. starting in the first quarter of 2040.
  • Earlier entry is possible under specified conditions, including patent expiration, adverse patent rulings or competing generic launches.
  • MSN will receive any more favorable market-entry or pre-launch terms subsequently granted to other parties.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-075166), on November 20, 2026, and is solely responsible for the information contained therein.